What is the average price target for CALUMET INC (CLMT) stock?
12 analysts have analysed CLMT and the average price target is 36.72 USD. This implies a price increase of 9.03% is expected in the next year compared to the current price of 33.68.
NASDAQ:CLMT • US1314281049
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CALUMET INC (CLMT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-12 | Goldman Sachs | Maintains | Buy -> Buy |
| 2026-01-30 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-11-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-22 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-08-12 | UBS | Maintains | Neutral -> Neutral |
| 2025-05-14 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-13 | B of A Securities | Initiate | Buy |
| 2025-04-30 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-03-17 | UBS | Upgrade | Sell -> Neutral |
| 2025-03-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-04 | UBS | Downgrade | Neutral -> Sell |
| 2025-01-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-11 | TD Cowen | Maintains | Buy -> Buy |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-21 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-10-17 | TD Cowen | Maintains | Buy -> Buy |
| 2024-10-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | TD Cowen | Maintains | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-05 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.181B -10.79% | 4.189B 0.20% | 4.137B -1.25% | 4.312B 4.23% | 4.825B 11.90% | 4.385B -9.12% | 5.777B 31.74% | 6.06B 4.90% | 6.286B 3.73% | 6.508B 3.53% | 6.739B 3.55% | |
| EBITDA YoY % growth | 417.5M 79.65% | 159.1M -61.89% | 203M 27.59% | 434.07M 113.83% | 534.7M 23.18% | 683.08M 27.75% | 851.7M 24.69% | 982.57M 15.37% | 1.07B 8.90% | 1.138B 6.36% | 1.194B 4.92% | |
| EBIT YoY % growth | 270.7M 101.86% | 10.1M -96.27% | 54.2M 436.63% | 220.51M 306.85% | 305.4M 38.50% | 339.14M 11.05% | 483.07M 42.44% | 605.47M 25.34% | 684.11M 12.99% | 742.76M 8.57% | 789.07M 6.23% | |
| Operating Margin | 6.47% | 0.24% | 1.31% | 5.11% | 6.33% | 7.73% | 8.36% | 9.99% | 10.88% | 11.41% | 11.71% | |
| EPS YoY % growth | 0.79 138.73% | -2.64 -434.18% | -1.11 57.95% | -0.14 87.14% | 0.35 342.86% | 1.37 294.12% | 2.26 65.67% | 2.91 28.38% | 3.60 23.86% | 4.14 15.01% | 4.60 11.08% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.45 82.67% | -0.15 91.40% | -0.02 -100.57% | -0.12 71.53% | -0.11 75.00% | 0.23 260.47% | 0.21 1,150.00% | 0.01 108.33% |
| Revenue Q2Q % growth | 990.93M -0.30% | 1.052B 2.47% | 1.144B 6.12% | 1.133B 9.09% | 928.2M -6.33% | 986.54M -6.22% | 980.02M -14.33% | 954.11M -15.79% |
| EBITDA Q2Q % growth | 67.947M 53.12% | 108.92M 78.22% | 127.32M 68.34% | 112.17M 49.17% | 110.42M 62.51% | 132.75M 21.88% | 132.91M 4.39% | 115.45M 2.92% |
| EBIT Q2Q % growth | 1.8M 101.62% | 42.56M 142.14% | 65.332M -80.16% | 45.365M 171.78% | 41.208M 2,189.33% | 71.808M 68.72% | 70.278M 7.57% | 51.51M 13.55% |
All data in USD
12 analysts have analysed CLMT and the average price target is 36.72 USD. This implies a price increase of 9.03% is expected in the next year compared to the current price of 33.68.
CALUMET INC (CLMT) will report earnings on 2026-05-08.
The consensus EPS estimate for the next earnings of CALUMET INC (CLMT) is -0.45 USD and the consensus revenue estimate is 990.93M USD.
The number of analysts covering CALUMET INC (CLMT) is 12.